Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease | Zendy

Helma Freitag | Zendy; Friederike Christen | Zendy; Florentine Lewens | Zendy; Irina Grass | Zendy; Franziska Briest | Zendy; Sara Iwaszkiewicz | Zendy; Britta Siegmund | Zendy; Patricia Grabowski | Zendy

Open Access

Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease

Author(s) -

Helma Freitag,

Friederike Christen,

Florentine Lewens,

Irina Grass,

Franziska Briest,

Sara Iwaszkiewicz,

Britta Siegmund,

Patricia Grabowski

Publication year - 2016

Publication title -

neuroendocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.493

H-Index - 101

eISSN - 1423-0194

pISSN - 0028-3835

DOI - 10.1159/000448843

Subject(s) - discovery and development of mtor inhibitors , pi3k/akt/mtor pathway , disease , medicine , neuroendocrine tumors , endocrinology , neuroscience , biology , signal transduction , microbiology and biotechnology

The characteristic clinical heterogeneity and mostly slow-growing behavior of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) cause problems in finding appropriate treatments. Thus, the current therapy options are not satisfactory. PKI-587 is a highly potent, novel dual inhibitor of PI3K and mTORC1/C2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research